Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01942265 · ClinicalTrials.gov registry record · Phase 2
H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 980
- Enrollment target
NCT01942265: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT01942265 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 980 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (637% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01942265, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 980 participants
- Enrollment target
Study Summary
This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria is designed to provide data on an A/H7N9 vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus.
Interventions
- DRUG AS03
- DRUG MF59
- BIOLOGICAL Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 980 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT01942265 record still lists
NCT01942265 is an interventional study that assigns participants to a tested intervention. The registered 980 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (637% higher).
The record links to 0 conditions, and to 3 interventions - of which AS03 is the first listed.
NCT01942265 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01942265 about?
NCT01942265 is a clinical study titled "H7N9 Mix and Match With AS03 and MF59 in Healthy Adults". This Phase II randomized, double-blinded, controlled study in up to 1000 males and non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all eligibility criteria is designed to provide data on an A/H7N9 vaccine made with HA antigen derived from the influenza A/Shanghai...
What is the current status of trial NCT01942265?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 980 participants. The study started on 2013-09. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01942265?
The interventions under investigation include: AS03 (DRUG), MF59 (DRUG), Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01942265?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01942265's enrollment target sits among peer trials
980 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06337097 · 980 participants · NA
STRICT - Surveillance With TRoponin During Immune Checkpoint Therapy
- NCT07070232 · 980 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- NCT07184931 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- NCT07184996 · 980 participants · Phase 3
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia